广东乐心医疗电子股份有限公司 独立董事 2024 年度述职报告 （周康） 本人作为广东乐心医疗电子股份有限公司（以下简称"公司"）的独立董事， 任职期间严格按照《公司法》《上市公司独立董事管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板 上市公司规范运作》等相关法律法规和《公司章程》《独立董事工作制度》等公 司相关的规定和要求，认真、勤勉、谨慎履行职责，积极出席相关会议，对各项 议案进行认真审议，对公司重大事项发表了明确意见，不受公司大股东、实际控 制人或者其他与公司存在利害关系的单位与个人的影响，充分发挥了独立董事及 各专门委员会委员的作用。一方面，严格审核公司提交董事会的相关事项，维护 公司和公众股东的合法权益，促进公司规范运作；另一方面发挥自己的专业优势， 积极关注和参与研究公司的发展，为公司的审计、内控、战略等工作提出了意见 和建议。现将本人在 2024 年担任公司独立董事期间的履职情况向各位股东汇报 如下： 一、个人基本情况 周康，男，1977 年出生，中国国籍，拥有境外永久居留权，硕士学历，拥有 注册会计师资格证书。曾任职于雷盛德奎实业有限公司 ...

广东乐心医疗电子股份有限公司 独立董事 2024 年度述职报告 （徐兴国） 本人作为广东乐心医疗电子股份有限公司（以下简称"公司"）的独立董 事，任职期间严格按照《公司法》《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 —创业板上市公司规范运作》等相关法律法规和《公司章程》《独立董事工作 制度》等公司相关的规定和要求，认真、勤勉、谨慎履行职责，积极出席相关 会议，对各项议案进行认真审议，对公司重大事项发表了明确意见，不受公司 大股东、实际控制人或者其他与公司存在利害关系的单位与个人的影响，充分 发挥了独立董事及各专门委员会委员的作用。一方面，严格审核公司提交董事 会的相关事项，维护公司和公众股东的合法权益，促进公司规范运作；另一方 面发挥自己的专业优势，积极关注和参与研究公司的发展，为公司的审计、内 控、战略等工作提出了意见和建议。现将本人在 2024 年担任公司独立董事期间 的履职情况向各位股东汇报如下： 一、个人基本情况 徐兴国，男，1978 年出生，中国国籍，无境外永久居留权，本科学历，拥有 注册会计师资格证。曾任职于三九医药股份有限公司 ...

董事、监事、高级管理人员持股变动管理制度 第一章 总则 董事、监事、高级管理人员持股变动管理制度 广东乐心医疗电子股份有限公司 第一条 为了进一步完善广东乐心医疗电子股份有限公司（以下简称"公司"或 "本公司"）董事、监事及高级管理人员所持本公司股份及其变动的管理，进一步明 确管理程序，做好信息披露工作，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司董事、监事 和高级管理人员所持本公司股份及其变动管理规则》《深圳证券交易所上市公司自 律监管指引第 10 号——股份变动管理》等有关法律、法规、规范性文件及公司章程 的规定，特制定本制度。 第二条 本制度适用于公司董事、监事和高级管理人员所持本公司股份及其变 动的管理。 第三条 公司董事、监事和高级管理人员所持本公司股份是指登记在其名下和 利用他人账户持有的所有本公司股份。公司董事、监事和高级管理人员从事融资融 券交易的，还包括记载在其信用账户内的本公司股份。 第四条 公司董事、监事和高级管理人员在买卖本公司股票及其衍生品种前，应 当知悉《公司法》《证券法》等法律关于内幕交易、操纵市场等禁止行为 ...

公司章程 广东乐心医疗电子股份有限公司 章 程 二〇二五年三月 第 1 页 | | | | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 5 | | 第三章 | 股份 | 5 | | 第一节 | | 股份发行 5 | | 第二节 | | 股份增减和回购 6 | | 第三节 | | 股份转让 8 | | 第四章 | | 股东和股东大会 9 | | 第一节 | | 股东 9 | | 第二节 | | 股东大会的一般规定 11 | | 第三节 | | 股东大会的召集 14 | | 第四节 | | 股东大会的提案与通知 15 | | 第五节 | | 股东大会的召开 17 | | 第六节 | | 股东大会的表决和决议 20 | | 第五章 | 董事会 | 24 | | 第一节 | | 董事 24 | | 第二节 | | 独立董事 27 | | 第三节 | | 董事会 31 | | 第四节 | | 董事会秘书 35 | | 第六章 | | 总经理及其他高级管理人员 36 | | 第七章 | 监事会 | 38 | | 第一节 | | 监事 38 | | 第二节 | ...

广东乐心医疗电子股份有限公司 独立董事 2024 年度述职报告 方式积极参加公司董事会会议，本人对报告期内董事会审议的所有议案均投了同 意票，无反对或弃权的情形。在股东大会会议中，本人积极听取中小投资的意见， 保持良好沟通交流。 2、出席董事会专门委员会与独立董事专门会议情况 （1）出席董事会专门委员会情况 报告期内，本人作为公司董事会提名委员会召集人，主持提名委员会的日常 工作。根据公司实际情况，本人召集召开三次提名委员会，会议中本人对候选人 的资料进行认真审核并发表明确意见，与其他提名委员会委员进行了充分沟通讨 论。本人日常加强与公司人力资源部门的沟通交流，勤勉尽责地履行职责，持续 研究与关注高级管理人员选拔制度，促使高级管理人员更好的为公司服务，提升 公司管理水平。 （胡安杨） 本人作为广东乐心医疗电子股份有限公司（以下简称"公司"）的独立董 事，任职期间严格按照《公司法》《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等相关法律法规和《公司章程》《独立董事工 作制度》等公司相关的规定和要求，认真、勤勉、谨慎履 ...

Financial Performance - The company's revenue for 2024 reached ¥983,982,436.12, representing an increase of 11.28% compared to ¥884,256,692.63 in 2023[33]. - Net profit attributable to shareholders for 2024 was ¥61,364,226.27, a significant increase of 78.55% from ¥34,367,303.85 in 2023[33]. - The net cash flow from operating activities improved by 60.30%, totaling ¥118,850,136.93 in 2024 compared to ¥74,141,927.21 in 2023[33]. - Basic earnings per share for 2024 were ¥0.2827, up 77.02% from ¥0.1597 in 2023[33]. - Total assets at the end of 2024 were ¥1,512,766,953.89, a decrease of 2.81% from ¥1,556,498,078.53 at the end of 2023[33]. - The weighted average return on equity for 2024 was 6.02%, an increase of 2.67 percentage points from 3.35% in 2023[33]. - The comprehensive gross profit margin improved to 35.07%, an increase of 4.13 percentage points compared to the same period last year[70]. - The main business revenue accounted for RMB 978,024,098.05, with a year-on-year growth of 11.28%[85]. - Home medical products generated RMB 664,736,928.12, showing an 18.51% increase from RMB 560,917,373.07 in the previous year[82]. - Sales expenses increased by 30.87% to ¥93,808,201.62, primarily due to higher sales commission costs[90]. - Management expenses rose by 21.61% to ¥88,443,748.31, mainly due to increased employee stock incentive costs[90]. Market Strategy and Expansion - The company aims to enhance its product competitiveness in overseas markets, focusing on North America, Europe, Australia, Asia-Pacific, and the Middle East, where overseas business revenue constitutes a significant portion of total revenue[10]. - The company acknowledges potential risks from international trade policies and economic conditions that could affect its overseas business expansion[10]. - The company is actively exploring new markets and enhancing customer structure to improve overall profitability[70]. - The company aims to strengthen high-quality growth and maintain steady development of its main business[80]. - The company is focused on expanding its product offerings and market presence in the rapidly growing OTC hearing aid market[92]. - The company is developing a medical-grade hearing aid that offers convenience and high cost-performance for users[92]. - The company is focused on improving user data management through advanced software for ECG data analysis and reporting[102]. Research and Development - The company is committed to improving its research and development capabilities by integrating industry-academia-medical collaborations and enhancing the stability and accuracy of existing products[12]. - The company invested CNY 96.81 million in R&D, accounting for 9.84% of its revenue during the reporting period, demonstrating a strong commitment to innovation and product development[64]. - The company has accumulated 653 domestic patents, including 129 invention patents, and has also registered 34 overseas patents, reflecting its focus on intellectual property and technology advancement[65]. - The company has developed a cardiovascular disease vertical AI model to provide affordable digital chronic disease management services, addressing the growing demand for proactive health management[60]. - The company has established a robust R&D team across multiple locations, ensuring continuous innovation and the ability to quickly adapt to market changes[64]. - The company is developing a new high-precision weighing sensor, aiming for a production efficiency increase of 20%[91]. - The company has completed the R&D of a blood pressure monitor that enhances measurement accuracy and stability, targeting various hypertension types[91]. - The company is developing a standardized platform for blood pressure monitors, which will significantly shorten product development cycles and improve efficiency[92]. Risk Management - The company faces management risks due to rapid growth, necessitating improvements in organizational structure and management systems to adapt to expanding operational scales[9]. - The company plans to strengthen its foreign exchange risk management mechanisms to mitigate the impact of currency fluctuations on pricing and profitability[14]. - The company has established a management system for financial derivative trading to mitigate operational risks[126]. - The company aims to conduct foreign exchange derivative trading to hedge against currency fluctuation risks, not for speculation[126]. Corporate Governance - The company emphasizes the importance of maintaining a strong governance structure with qualified independent directors[171]. - The board of directors held a total of 19 meetings during the reporting period, with the latest meeting on October 25, 2024[184]. - The audit committee approved significant resolutions, including the annual audit work report and the internal control self-assessment report for 2023[189]. - The company is committed to maintaining high-quality sustainable development and protecting the rights of minority shareholders[188]. - The company has not reported any penalties from regulatory authorities for directors and supervisors in the last three years[179]. Employee and Management Changes - The total number of employees at the end of the reporting period is 1,182, with 520 in the parent company and 662 in major subsidiaries[194]. - The company has experienced changes in its management team, with two resignations in 2024 due to personal reasons[169]. - The company has a structured remuneration decision process based on performance and responsibilities[180]. - The average remuneration for supervisors was approximately CNY 30,000[182]. Product Development and Innovation - The company launched the "iSENSE series" twelve-lead smart ECG shirt, which received regulatory approval as a Class II medical device in Guangdong Province[72]. - The company is expanding its product matrix with medical-grade remote health monitoring devices, including smart blood pressure monitors and AI-assisted diagnostic ECG shirts[71]. - The company has completed the medical certification for its real-time ECG monitoring product, enhancing its capabilities in remote cardiac monitoring[92]. - The company has successfully developed a remote smart blood glucose meter, enabling real-time data transmission to monitoring terminals[98]. - The company is developing a stylish light luxury health product line with the LED strip Bluetooth body fat scale, having finalized industrial design and currently working on hardware design[99]. Financial Overview - The total cash inflow from operating activities reached ¥1,115,157,043.11, reflecting a year-on-year increase of 16.75%[111]. - The company reported a net cash outflow from investment activities of ¥15,204,135.58, a significant decrease of 182.80% compared to the previous year due to increased purchases of fixed assets[111]. - The total number of medical device registration certificates at the end of the reporting period was 23, an increase from 18 in the same period last year[110]. - The company has received CE certification for multiple electronic blood pressure monitors, with certificates valid until December 31, 2028[108].

Group 1 - China Aluminum reported a net profit of 12.4 billion yuan for 2024, an increase of 85.38% year-on-year, with a proposed cash dividend of 0.135 yuan per share [1] - Lihua Technology's net profit for 2024 decreased by 25.41% to 245 million yuan, with a proposed cash dividend of 0.7 yuan per 10 shares [1][2] - Zhongjing Food achieved a net profit of 175 million yuan in 2024, up 1.81% year-on-year, proposing a cash dividend of 8 yuan per 10 shares [3][4] - Sanwei Chemical's net profit fell by 6.92% to 263 million yuan, with a proposed cash dividend of 3 yuan per 10 shares [5] - Meino Biological's project for corn protein processing has received construction approval, with an investment of approximately 391 million yuan [6][7] Group 2 - Guangdian Electric's net profit surged by 411.28% to 74.73 million yuan, proposing a cash dividend of 0.7 yuan per 10 shares [13][14] - Xin'ao Co. reported a net profit of 4.493 billion yuan for 2024, down 36.64%, with a proposed cash dividend of 10.3 yuan per 10 shares [15] - Huaren Pharmaceutical's subsidiary received approval for a raw material drug, enhancing its product line [16] - Huanxin Technology received a project confirmation from BAIC Group for two display screen products, expected to enter mass supply [17] - Haitong Development plans to purchase four bulk carriers for a total of 59.25 million USD to expand its fleet [18] Group 3 - Guochuang High-tech won a bid for an asphalt procurement project worth 128 million yuan [22][23] - Huayi Pharmaceutical's subsidiary received overseas marketing approvals for several products [24] - Haisco's innovative drug HSK41959 has received clinical trial approval [25] - Hetai Machinery's subsidiary obtained a patent for a dust-proof chain technology [28] - Le Xin Medical's fetal heart rate monitor registration renewal application has been accepted [29] Group 4 - Feilong Co. became a designated supplier for an international client's electronic oil pump project, with expected sales of approximately 160 million yuan [29] - Yunnan Copper reported a net profit of 1.265 billion yuan for 2024, down 19.9%, with a proposed cash dividend of 2.4 yuan per 10 shares [42] - China Merchants Bank's net profit increased by 1.22% to 148.39 billion yuan, proposing a cash dividend of 20 yuan per 10 shares [43] - Shuanghui Development's net profit decreased by 1.26% to 4.989 billion yuan, with a proposed cash dividend of 7.5 yuan per 10 shares [44]

证券代码：300562 证券简称：乐心医疗 公告编号：2025-010 广东乐心医疗电子股份有限公司 关于延续医疗器械注册证获得受理的公告 乐心医疗 2025 年公告 上述胎儿心率记录仪由主机、硅胶套、无线充电器及移动端软件组成，其中 移动端软件由关于模块、用户管理模块、设备管理模块、数据显示模块、数据管 理模块及数据传输模块组成。该产品采用被动式采集胎心音检测，类似听诊器的 被动式原理，外观设计小巧便携，适用于对妊娠 32 周以上单胎孕妇的胎心曲线 记录，提供数据给孕妇，缓解焦虑，提高孕期质量。 公司定位于"医疗级远程健康监测设备及服务提供商"，始终高度重视医疗 器械标准符合性，推动全系列产品向医疗级方向发展。上述医疗器械延续注册符 合公司实际情况，有利于公司进一步开拓业务，增强综合竞争力，对公司经营发 展起到积极作用。上述医疗器械延续注册事宜目前尚处于受理阶段，后续仍需相 关机构进一步核准认证，评审在各阶段所需的时间和结果均具有一定的不确定性。 公司目前尚无法预测其对公司未来业绩的影响，敬请广大投资者注意投资风险。 特此公告。 广东乐心医疗电子股份有限公司 董事会 二〇二五年三月二十六日 本公司及董事会全 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5] Core Views - The company aims to become a global leader in remote health monitoring, leveraging opportunities in the health IoT and digital health services sectors [4] - Revenue projections for 2024-2026 are estimated at 1.025 billion, 1.225 billion, and 1.443 billion yuan, with year-on-year growth rates of 16%, 20%, and 18% respectively [5] - The company has shown significant improvement in profitability, with net profit forecasts for 2024-2026 at 62.18 million, 88.65 million, and 124.03 million yuan, reflecting growth rates of 81%, 43%, and 40% respectively [5] Company Overview - The company was founded in 2002 and has shifted its focus towards smart health, aiming to align with national strategies for "Healthy China" and "Digital China" [18] - The largest shareholder, Pan Weichao, holds 33.14% of the company and has extensive experience in the home medical electronics sector [20] - The company has actively optimized its customer and product structure since 2022, leading to a significant increase in gross margin [21] Financial Performance - In 2023, the company reported a gross margin of 30.94%, up 7.24 percentage points year-on-year, despite a revenue decline of 16.98% [21] - For the first nine months of 2024, revenue reached 755.6 million yuan, a 24.39% increase year-on-year, with net profit at 51 million yuan, up 232.83% [22] Business Segments - The company operates in two main segments: health IoT and digital health services, focusing on medical-grade health IoT devices and remote health management solutions [27] - The health IoT segment includes medical-grade devices and RPM solutions, while the digital health services segment encompasses digital blood pressure management and remote ECG services [27] Product Development - The company has introduced new products such as hearing aids and smart ECG clothing, with the smart ring expected to launch in 2025 [6] - The company has established strong partnerships with leading health IoT companies, enhancing its market presence [35] Market Potential - The global market for home medical devices is projected to grow significantly, with the wearable medical device market in China valued at 22.08 billion yuan in 2023 [34] - The wearable device market is expected to reach 431.74 billion USD by 2034, indicating substantial growth opportunities for the company [41]

证券研究报告：医药生物 | 公司深度报告 2025 年 3 月 14 日 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 15.58 | | --- | --- | | 总股本/流通股本（亿股）2.17 | / 1.61 | | 总市值/流通市值（亿元）34 | / 25 | | 52 周内最高/最低价 | 17.56 / 7.55 | | 资产负债率(%) | 34.2% | | 市盈率 | 97.56 | | 第一大股东 | 潘伟潮 | 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 研究助理:陈峻 SAC 登记编号:S1340123110013 Email:chenjun@cnpsec.com 乐心医疗(300562) 公司医疗垂直领域大模型赋能慢病管理设备，"AI + 可穿戴 + 医疗"有望迎来爆发 l 公司致力于成为"远程健康监测全球领导者" 乐心医疗紧抓健康 IoT 和数字健康服务行业高速发展机遇，积极 顺应"健康中国"和"数字中国"建设国家战略发展方向，凭借多年 在智能健康硬件、大 ...